Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Other financing activities (2018 - 2022)

Zevra Therapeutics' Other financing activities history spans 6 years, with the latest figure at -$68000.0 for Q4 2022.

  • For Q4 2022, Other financing activities rose 95.59% year-over-year to -$68000.0; the TTM value through Sep 2024 reached -$68000.0, changed 0.0%, while the annual FY2024 figure was $2.1 million, N/A changed from the prior year.
  • Other financing activities reached -$68000.0 in Q4 2022 per ZVRA's latest filing, down from $68000.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $2.9 million in Q1 2021 to a low of -$1.8 million in Q2 2021.
  • Average Other financing activities over 4 years is $156600.0, with a median of $48500.0 recorded in 2020.
  • The largest YoY upside for Other financing activities was 8373.53% in 2021 against a maximum downside of 11769.23% in 2021.
  • A 4-year view of Other financing activities shows it stood at $144000.0 in 2018, then plummeted by 109.03% to -$13000.0 in 2020, then plummeted by 11769.23% to -$1.5 million in 2021, then surged by 95.59% to -$68000.0 in 2022.
  • Per Business Quant, the three most recent readings for ZVRA's Other financing activities are -$68000.0 (Q4 2022), $68000.0 (Q1 2022), and -$1.5 million (Q4 2021).